(Stroke. 2003;34:600.)
© 2003 American Heart Association, Inc.
Original Contributions |
From the Department of Clinical Neurosciences, St Georges Hospital Medical School, London, UK (P.R., P.J-D., H.S.M.), and Department of Neurology, Johann Wolfgang Goethe University Frankfurt am Main, Frankfurt am Main, Germany (M.S., A.B., S. von K.).
Correspondence to Paul Risley, Department of Clinical Neurosciences, St Georges Hospital Medical School, Cranmer Terr, Tooting, London SW17 0RE, UK. E-mail prisley{at}sghms.ac.uk
| Abstract |
|---|
|
|
|---|
Methods A community population (n=992; aged 50 to 65 years) underwent genotypic examination for the CD14 -159 polymorphism by restriction fragment length polymorphism analysis.
Results The CC genotype was associated with increased CCA IMT. The age- and sex-adjusted odds ratio for IMT above the 75th percentile was 1.63 (95% CI, 1.19 to 2.24; P=0.002) and 1.70 (95% CI, 1.18 to 2.44; P=0.004) after additional adjustment for conventional risk factors. This gene effect was found only in current smokers and ex-smokers. Multivariate analysis in this group (n=503) increased the odds ratio to 2.02 (95% CI, 1.23 to 3.34; P=0.006). No significant interactions were found in nonsmokers or with alcohol consumption.
Conclusions The CD14 -159 polymorphism is associated with increased CCA IMT in smokers from a general population. CD14 may modulate the inflammatory effects of smoking in atherogenesis.
Key Words: antigens, CD14 atherosclerosis cigarette smoking polymorphism
| Introduction |
|---|
|
|
|---|
Inflammation is now accepted as a major component of atherosclerosis.5 Certain conventional risk factors, including cigarette smoking and obesity, are associated with elevated levels of inflammatory markers.6 It has been suggested that these risk factors may exert part of their risk by promoting inflammation.7,8 In particular, bacterial endotoxin, a potent mediator of inflammation, has been identified as an active component of cigarette smoke,9 and smokers have elevated plasma levels of endotoxin.10 Circulating levels of endotoxin, in turn, have been shown to independently predict incident atherosclerosis measured by carotid ultrasound,10 but the ability of endotoxin to promote atherogenesis appears to be dependent on the degree of inflammatory response it provokes.11 The soluble form of the endotoxin receptor (sCD14) has been shown to enhance the endotoxin-neutralization capacity of plasma.1214 A polymorphism in the promoter region of the CD14 gene has been associated with altered levels of this circulating endotoxin receptor.15
We hypothesized that this functional polymorphism could predispose to atherosclerosis by modulating the host inflammatory response to endotoxin. In a large community population of middle-aged individuals, we studied the impact of the CD14 -159 genotype on early atherosclerosis using common carotid artery (CCA) intima-media thickness (IMT), measured by ultrasound. We hypothesized that any effect of this polymorphism would be most pronounced in individuals who smoked and therefore had greater environmental exposure to bacterial endotoxin.
| Subjects and Methods |
|---|
|
|
|---|
Biochemical Measurements
Fasting blood samples were taken for estimation of serum cholesterol, glycosylated hemoglobin A1c (HbA1c), and fibrinogen. Total serum cholesterol was determined enzymatically with the use of a commercial kit (Boehringer). LDL cholesterol was measured with the heparin-calcium precipitation method and HDL cholesterol with the phosphotungstic acid precipitation method. Glycosylated hemoglobin (glyc-Hb-%) was determined by the IMX method (Abbott). HbA1c concentration was calculated according to the formula HbA1c=(glyc-Hb-%+1.76)/1.49.19 Fibrinogen was determined from citrated plasma by the Clauss method (Multifibren, Behringwerke). C-reactive protein (CRP) concentration was measured by a high-sensitivity in-house enzyme-linked immunosorbent assay (range, 0.6 to 40 µg/L).19
Ultrasound Imaging
The method used to determine CCA IMT has been described in detail before.19 In brief, we used a 7.5- to 10.0-MHz linear array transducer (P700SE, Phillips Medical System). IMT measurements were performed off-line with the use of automated imaging processing software that has been described previously.19 Blood/intimal and medial/adventitial interfaces were automatically detected with the use of a gray valuebased edge detection algorithm. The mean length of the arterial segment in which IMT was determined was 14.35 mm for the left CCA and 12.85 mm for the right CCA. Interobserver reliabilities were assessed in a sample of 15 subjects (54 arterial segments) in whom IMT was measured by 4 "blinded" observers. Linear regression analyses revealed high correlation coefficients (r=0.92 to 0.99), and, according to the method described by Bland and Altman,20 the ±2 SD of the difference between 2 observers varied between 0.03 and 0.06 mm. Intraobserver retest reliability was determined from repetitive examinations of 35 subjects (102 arterial segments) by 3 independent observers. Linear regression showed high coefficients (r=0.91 to 0.98), and the ±2 SD of the difference between the 2 examinations varied between 0.04 and 0.06 mm.
Laboratory Methods
DNA was available for 992 subjects. DNA was extracted from whole blood with the use of Nucleon kits (Tepnel Life Sciences). The polymorphism underwent genotypic analysis by polymerase chain reaction, resulting in a 497base pair (bp) product, followed by restriction enzyme digestion with HaeIII (Bioline), producing a fragment of 199 bp, plus fragments of 298 bp for the T allele or 155 and 143 bp (appearing as a single band) for the C allele. Products were visualized on agarose gel stained with ethidium bromide. Genotypes were confirmed by sequencing. Polymerase chain reaction conditions and primers were selected according to the methods of Baldini et al.15
Statistical Analysis
Data were analyzed with the use of SPSS (version 10). We analyzed the relationship between genotype and CCA IMT in 2 ways. First, we used CCA IMT as a continuous variable using linear regression. The mean of the right and left CCA IMT values was skewed, and therefore the reciprocal IMT was used to normalize the distribution. Geometric mean IMT values are given in the text for clarity. For the second analysis, we calculated odds ratios for IMT above the 75th percentile using multiple logistic regression. This second analysis was performed because previously published studies suggested that the relationship between IMT and risk of future vascular events is nonlinear and is strongest at higher values of IMT. In both analyses, a genotype-smoking interaction term was included to look for evidence of gene-environment interaction. The effects of genotype on CCA IMT were examined for additive (number of alleles), dominant (carriage of C allele versus TT homozygotes), and recessive (CC homozygotes versus carriage of the T allele) relationships. Age, BMI, mean systolic and diastolic blood pressures, and LDL/HDL cholesterol were normally distributed. We categorized pack-years of smoking by 10-year intervals. In this community population CRP was negatively skewed, with many subjects below the limits of measurement, and therefore CRP was categorized into quartiles.
| Results |
|---|
|
|
|---|
|
CD14 Polymorphism and Cardiovascular Risk Factors
The genotype distribution was 24.8% for CC, 50.8% for CT, and 24.4% for TT. This was in Hardy-Weinberg equilibrium (P=0.999). Analysis of the relationships between genotype and the aforementioned cardiovascular risk factors revealed no significant associations.
CCA IMT and Genotype
When IMT was analyzed as a continuous variable, the C allele of the CD14 polymorphism was associated with increased CCA IMT. This finding was significant when we used an additive model (allele frequency) (P=0.049) and for CC homozygotes versus CT/TT combined (P=0.022) (Table 2).
|
Analysis of IMT by highest quartile showed that the CC genotype was significantly more common in the top quartile; 33.3% of the CC genotype was found in this quartile compared with 23.7% and 23.1% of the CT and TT genotypes, respectively (P=0.009 for CC compared with TT and P=0.011 for linear trend). The odds ratio for IMT above the 75th percentile was 1.63 (95% CI, 1.19 to 2.24; P=0.002) for CC compared with both the other genotypes combined. After multivariate analysis controlling for conventional risk factors, the odds ratio for the CC genotype was not weakened at 1.70 (95% CI, 1.18 to 2.44; P=0.004).
Environment Interactions
There was a significant interaction between CD14 genotype and smoking (P for interaction=0.008). Specifically, the relationship between genotype and IMT was stronger in smokers and absent in those who had never smoked (Table 3 and Figure). Additionally, there was evidence of a graded relationship between the number of pack-years smoked and the effect of CD14 genotype on IMT. Increasing pack-years of smoking resulted in a linear increase in IMT with carriage of the C allele (P<0.001, adjusted for cardiovascular risk factors). The increase in IMT was highest in the CC homozygotes. In contrast, there was no linear relationship in the TT homozygotes (P=0.704, adjusted for cardiovascular risk factors). The relationship with smoking was not affected by potential confounding of factors, including exercise, total energy expenditure per day, or use of antihypertensive treatment.
|
|
No significant associations were shown between increased IMT, CD14 genotype, and BMI or level of alcohol consumption.
| Discussion |
|---|
|
|
|---|
Our study is one of the first to demonstrate gene-environment interactions in the pathogenesis of carotid atherosclerosis. There are a number of pathophysiological explanations for the interaction with smoking. Previous work has shown that TT homozygotes for the CD14 -159 polymorphism have elevated levels of sCD1415 and that carriage of the T allele results in upregulation of transcription of CD14.21 Increases in sCD14 can decrease monocyte response to endotoxin by clearance via lipoproteins. This leads to a decreased inflammatory response.22 A strong correlation between sCD14 and the endotoxin-neutralizing capacity of plasma has also been demonstrated.23 Data from the Bruneck atherosclerosis study showed that subjects with high endotoxin levels were at risk of increased IMT only if they also had increased inflammatory markers.11 Individuals with the CC genotype express lower levels of CD1421 and therefore may also be less able to clear endotoxin and other CD14 ligands, resulting in chronic low-grade inflammation. Conversely, carriage of the T allele upregulates CD14 expression and may enable a more robust response to acute challenge but better clearance of ligand and reduced chronic inflammation. The effect of smoking on IMT may arise from the bioactive endotoxin found in cigarette smoke.9 The increased risk of lower respiratory tract infection seen in smokers24 may also increase the antigenic load in this group. Risk of atherosclerosis from endotoxemia has been found to be increased in current and past smokers compared with nonsmokers.10 A genetic predisposition that reduces clearance of endotoxin would therefore be expected to enhance the inflammatory consequences of smoking. The CC genotype may be such a genotype. The measurement of endotoxin alone may not be sufficient as an indication of potential CD14 stimulation. The CD14 receptor is known to respond to a range of factors and has been proposed as an "ante-antibody" for the innate immune system.25 If this is the case, then activation of CD14 may arise from many different stimuli. In this cohort no significant association was found between CRP and CD14 genotype. We do not believe that this lack of association invalidates our findings because the gene-environment interactions observed may be operating via alternative inflammatory pathways or more localized inflammation within atherosclerotic plaque.
The association we found was stronger when relationships were studied with an increased IMT, indicated by a value in the highest quartile, compared with when IMT values across the range were correlated with genotype. This is consistent with previous studies suggesting that risk factors and future risk correlate better with an increased IMT above a certain value rather than with IMT treated as a continuous variable. For example, the Atherosclerosis Risk in Communities (ARIC) Study found that the relationship between IMT and risk of coronary heart disease was nonlinear and that it was strongest at the higher values of IMT.26
In this community population, the number of subjects with carotid plaque was relatively low, at only 6.3%. Therefore, there were too few cases to allow meaningful statistical analysis of the association between genotype and plaque. Previous similar studies have reported higher incidence of plaque.27,28 The low frequency we found may reflect a true lower prevalence in our population, but direct comparison is difficult because of differences in both study groups and in definition of plaque. We defined plaque as an IMT >1.7 mm, while other studies have used definitions ranging from 1.0 to 1.7 mm.27,29,30 This study therefore addresses the mechanisms involved in the initiation of carotid atherogenesis, not the later progression of established plaques. The pathogenesis of atherosclerosis is complex and multifactorial. Although the relationship between the CD14 gene and carotid IMT remains circumstantial at this time, the findings of this study support the hypothesis that gene-environment interactions are potentially important determinants of atherosclerosis. The role of "conventional risks" is well documented, but the input from the subjects genes has only recently begun to be explored.
Measurement of increased CCA IMT has previously been used as a measure of subclinical atherosclerosis in a general population.29 CCA IMT measured by ultrasound correlates well with histological measurements of the artery wall.30 Prospective studies have shown that increased IMT independently predicts future cardiovascular event risk, including stroke.31,32 Measurement of CCA IMT, as opposed to other sites, appears to provide the best reproducibility.33
These findings support a role for the CD14 endotoxin receptor in atherosclerosis. Genetic variation in the endotoxin receptor may act to mediate the risk of smoking on vascular disease.
| Acknowledgments |
|---|
Received April 4, 2002; revision received August 19, 2002; accepted September 17, 2002.
| References |
|---|
|
|
|---|
2. Duggirala R, Gonzalez Villalpando C, OLeary DH, Stern MP, Blangero J. Genetic basis of variation in carotid artery wall thickness. Stroke. 1996; 27: 833837.
3. Malin R, Loimaala A, Nenonen A, Mercuri M, Vuori I, Pasanen M, Oja P, Bond G, Koivula T, Lehtimaki T. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism. 2001; 50: 10951101.[CrossRef][Medline] [Order article via Infotrieve]
4. Wang XL, Rainwater DL, VandeBerg JF, Mitchell BD, Mahaney MC. Genetic contributions to plasma total antioxidant activity. Arterioscler Thromb Vasc Biol. 2001; 21: 11901195.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115126.
6. Zevin S, Saunders S, Gourlay SG, Jacob P, Benowitz NL. Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol. 2001; 38: 16331638.
7. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148: 209214.[CrossRef][Medline] [Order article via Infotrieve]
8. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17: 21672176.
9. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999; 115: 829835.
10. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J Am Coll Cardiol. 1999; 34: 19751981.
11. Wiedermann CJ, Kiechl S, Schratzberger P, Dunzendorfer S, Weiss G, Willeit J. The role of immune activation in endotoxin-induced atherogenesis. J Endotoxin Res. 2001; 7: 322326.[CrossRef][Medline] [Order article via Infotrieve]
12. Hiki N, Berger D, Dentener MA, Mimura Y, Buurman WA, Prigl C, Seidelmann M, Tsuji E, Kaminishi M, Beger HG. Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clin Diagn Lab Immunol. 1999; 6: 844850.
13. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol. 1995; 154: 65296532.[Abstract]
14. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol. 1994; 152: 58685876.[Abstract]
15. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol. 1999; 20: 976983.
16. Sitzer M, Skutta M, Siebler M, Sitzer G, Siegrist J, Steinmetz H. Modifiable stroke risk factors in volunteers willing to participate in a prevention program. Neuroepidemiology. 1998; 17: 179187.[CrossRef][Medline] [Order article via Infotrieve]
17. Helmert U, Shea S, Herman B, Greiser E. Relationship of social class characteristics and risk factors for coronary heart disease in West Germany. Public Health. 1990; 104: 399416.[CrossRef][Medline] [Order article via Infotrieve]
18. Giovannucci E, Colditz G, Stampfer MJ, Rimm EB, Litin L, Sampson L, Willett WC. The assessment of alcohol consumption by a simple self-administered questionnaire. Am J Epidemiol. 1991; 133: 810817.
19. Sitzer M, Markus HS, Mendall MA, Liehr R, Knorr U, Steinmetz H. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk. 2002; 9: 97103.[CrossRef][Medline] [Order article via Infotrieve]
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1: 307310.[CrossRef][Medline] [Order article via Infotrieve]
21. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, Vercelli D. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol. 2001; 167: 58385844.
22. Kitchens RL, Thompson PA, Viriyakosol S, OKeefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest. 2001; 108: 485493.[CrossRef][Medline] [Order article via Infotrieve]
23. Hiki N, Berger D, Mimura Y, Frick J, Dentener MA, Buurman WA, Seidelmann M, Kaminishi M, Beger HG. Release of endotoxin-binding proteins during major elective surgery: role of soluble CD14 in phagocytic activation. World J Surg. 2000; 24: 499506.[CrossRef][Medline] [Order article via Infotrieve]
24. Kelsey MC, Mitchell CA, Griffin M, Spencer RC, Emmerson AM. Prevalence of lower respiratory tract infections in hospitalized patients in the United Kingdom and Eire: results from the Second National Prevalence Survey. J Hosp Infect. 2000; 46: 1222.[CrossRef][Medline] [Order article via Infotrieve]
25. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity. 1994; 1: 509516.[CrossRef][Medline] [Order article via Infotrieve]
26. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 19871993. Am J Epidemiol. 1997; 146: 483494.
27. Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, Dhanjil S, Griffin M, Belcaro G, Rumley A, Lowe GD. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 1999; 30: 841850.
28. Zureik M, Ducimetiere P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, Magne C. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. Arterioscler Thromb Vasc Biol. 2000; 20: 16221629.
29. Ferrieres J, Elias A, Ruidavets JB, Cantet C, Bongard V, Fauvel J, Boccalon H. Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population. J Hypertens. 1999; 17: 743748.[CrossRef][Medline] [Order article via Infotrieve]
30. Gamble G, Beaumont B, Smith H, Zorn J, Sanders G, Merrilees M, MacMahon S, Sharpe N. B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. Atherosclerosis. 1993; 102: 163173.[CrossRef][Medline] [Order article via Infotrieve]
31. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997; 96: 14321437.
32. OLeary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340: 1422.
33. Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke. 1997; 28: 665671.
This article has been cited by other articles:
![]() |
J. N. Redgrave, P. Gallagher, J. K. Lovett, and P. M. Rothwell Critical Cap Thickness and Rupture in Symptomatic Carotid Plaques: The Oxford Plaque Study Stroke, June 1, 2008; 39(6): 1722 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Markus Genes for stroke J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1229 - 1231. [Full Text] [PDF] |
||||
![]() |
T. A. Manolio, E. Boerwinkle, C. J. O'Donnell, and A. F. Wilson Genetics of Ultrasonographic Carotid Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1567 - 1577. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau Genetic Markers: Progress and Potential for Cardiovascular Disease Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58. [Full Text] [PDF] |
||||
![]() |
A. R. O'Donnell, B. G. Toelle, G. B. Marks, C. M. Hayden, I. A. Laing, J. K. Peat, J. Goldblatt, and P. N. Le Souef Age-specific Relationship between CD14 and Atopy in a Cohort Assessed from Age 8 to 25 Years Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 615 - 622. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |